Top Page
Ascentage Pharma Group International
(6855)
Ascentage Pharma Group International (6855) vs. iShares MSCI Hong Kong ETF (EWH)
Ascentage Pharma Group International Business Overview & Revenue Model
Ascentage Pharma Group International Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 980.65M | 221.98M | 209.71M | 27.91M | 12.45M | Gross Profit |
| 951.57M | 191.44M | 187.71M | 24.58M | 10.48M | EBIT |
| -378.80M | -891.99M | -883.41M | -933.17M | -684.43M | EBITDA |
| -299.63M | -743.61M | -835.99M | -915.99M | -641.77M | Net Income Common Stockholders |
| -405.43M | -925.64M | -882.92M | -782.42M | -677.61M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.26B | 1.10B | 1.50B | 1.75B | 1.03B | Total Assets |
| 2.62B | 2.50B | 2.83B | 2.94B | 1.73B | Total Debt |
| 1.67B | 1.80B | 1.79B | 1.08B | 529.70M | Net Debt |
| 407.29M | 726.30M | 300.49M | -659.53M | -494.70M | Total Liabilities |
| 2.34B | 2.43B | 2.42B | 1.71B | 884.42M | Stockholders Equity |
| 264.19M | 60.42M | 408.66M | 1.23B | 846.62M |
| Cash Flow | Free Cash Flow | |||
| -135.65M | -782.92M | -857.20M | -1.04B | -859.88M | Operating Cash Flow |
| -111.36M | -726.08M | -653.91M | -604.68M | -609.96M | Investing Cash Flow |
| -362.04M | 21.92M | -384.61M | -466.52M | -107.37M | Financing Cash Flow |
| 314.77M | 368.75M | 619.27M | 1.78B | 1.04B |
Ascentage Pharma Group International Technical Analysis
Ascentage Pharma Group International Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $113.92B | 31.58 | 8.17% | ― | 7.52% | -1.92% | |
62 Neutral | HK$3.78B | 21.21 | 4.47% | ― | -9.75% | ― | |
59 Neutral | HK$35.82B | ― | -19.78% | ― | 25.96% | 39.58% | |
55 Neutral | HK$86.03B | ― | -8.98% | ― | -54.66% | -123.11% | |
54 Neutral | HK$21.54B | ― | -253.12% | ― | 330.23% | 59.68% | |
54 Neutral | $5.37B | 3.26 | -45.10% | 3.30% | 16.81% | 0.02% | |
46 Neutral | €4.33B | ― | -10.43% | ― | 36.76% | 42.89% |
Ascentage Pharma Group International Corporate Events
Ascentage Pharma announced promising results from 13 studies at the 2025 European Hematology Association Congress, highlighting the potential of its novel drug olverembatinib and investigational EED inhibitor APG-5918. Olverembatinib, a third-generation tyrosine kinase inhibitor, showed significant clinical benefits in treating Philadelphia chromosome-positive acute lymphoblastic leukemia, with high remission rates and favorable tolerability. The studies also revealed the drug’s potential in combination therapies, offering more treatment options for patients. APG-5918 demonstrated potent antitumor activity in preclinical studies, supporting its further clinical development.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
Ascentage Pharma announced the presentation of new clinical data from two ongoing studies at the 2025 ASCO Annual Meeting. The studies involve lisaftoclax in blood cancers and alrizomadlin in solid tumors, both showing promising antitumor activity. The data supports further clinical development, potentially enhancing Ascentage Pharma’s position in the oncology market and offering new treatment options for patients.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
Ascentage Pharma Group International announced the successful passage of all resolutions at its Annual General Meeting held on May 19, 2025. Key resolutions included the re-election of board members, authorization of director remuneration, reappointment of Ernst & Young as auditors, and granting mandates for share issuance and repurchase. These decisions reflect the company’s strategic direction and governance stability, which may positively impact investor confidence and support its ongoing growth and development initiatives.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
Ascentage Pharma Group International has announced a supplemental notice for its Annual General Meeting scheduled for May 19, 2025, in Suzhou, China. The meeting will address additional resolutions concerning amendments to the company’s RSU Schemes and Share Option Scheme, as well as the approval of limits on shares issued under these schemes. These resolutions are significant for the company’s governance and could impact its operational strategies and stakeholder interests.
Ascentage Pharma presented results from five preclinical studies at the 2025 AACR Annual Meeting, showcasing the synergistic effects of their drug candidates olverembatinib and lisaftoclax. The studies demonstrated that the combination of these drugs effectively overcomes resistance to venetoclax in acute myeloid leukemia models, suggesting a promising new therapeutic strategy. Additionally, the combination showed antitumor effects in T-cell acute lymphoblastic leukemia models, highlighting its potential impact on treatment options for high-risk hematologic cancers.
Ascentage Pharma announced that data from two of its clinical studies will be presented at the 2025 ASCO Annual Meeting, a prominent event in the oncology field. The presentations will feature results from studies on lisaftoclax and alrizomadlin, highlighting the company’s advancements in cancer treatment and potentially enhancing its position in the oncology market.
Ascentage Pharma has announced the inclusion of its novel drugs, lisaftoclax and olverembatinib, in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax, a Bcl-2 selective inhibitor, received its first recommendation for treating lymphoid malignancies, marking a significant milestone for the company in the field of hematological malignancies. Olverembatinib, a next-generation tyrosine kinase inhibitor, received an upgraded recommendation for treating leukemias in children and adolescents, highlighting its vital role in addressing BCR-ABL mutations. These developments enhance Ascentage Pharma’s industry positioning and expand its treatment options, potentially benefiting patients with specific cancer mutations.
Ascentage Pharma Group International has announced its upcoming Annual General Meeting (AGM) scheduled for May 19, 2025, in Suzhou, China. Key agenda items include the adoption of the company’s financial statements for 2024, re-election of several directors, and re-appointment of Ernst & Young as auditors. Additionally, the meeting will consider granting a mandate to the directors to manage share allotments, potentially impacting the company’s operational flexibility and shareholder value.
Ascentage Pharma Group International announced the purchase of 50,000 shares by the Trustee for the 2022 RSU Scheme, representing approximately 0.014% of the total issued shares. This move is part of the company’s ongoing efforts to satisfy the RSUs upon exercise, reflecting its commitment to employee incentives and aligning with its strategic goals.
Ascentage Pharma Group International announced the purchase of 50,000 shares by a trustee for its 2022 Restricted Share Unit (RSU) Scheme, representing approximately 0.014% of the total issued shares. This purchase is part of the company’s ongoing efforts to satisfy RSUs upon exercise, reflecting its commitment to employee incentive programs and potentially enhancing shareholder value.
Ascentage Pharma reported a significant revenue increase of 342% in 2024, driven by Takeda’s option payment and strong sales of olverembatinib in China. The company completed a U.S. IPO on Nasdaq, raising $132.5 million, and advanced its clinical programs with ten registrational trials underway, including two FDA-cleared trials. The acceptance of lisaftoclax for NDA review with Priority Review designation in China marks a pivotal step for the company, highlighting its commitment to oncology innovation and expanding its global footprint.
Ascentage Pharma announced the selection of five preclinical studies from its innovative pipeline for presentation at the 2025 American Association of Cancer Research Annual Meeting. The studies highlight promising results from drug candidates such as olverembatinib, lisaftoclax, APG-2449, APG-5918, and AS03157, showcasing the company’s advancements in cancer therapeutics. This announcement underscores Ascentage Pharma’s commitment to advancing cancer treatment and may enhance its position in the oncology sector, potentially benefiting stakeholders and patients alike.